Remove authors iqvia-technologies
article thumbnail

Improving trial predictability: leveraging AI-powered analytics to guide trial design, strategy, and operations

pharmaphorum

Using data-informed insights derived by effectively implemented datasets, artificial intelligence/machine learning capabilities, and technology sponsors can realise increased predictability in their study planning from protocol design through enrolment strategy. About the authors. Critical analysis in protocol design. 2016;18(1).

article thumbnail

Innovative Medicines Fund and the opportunity for ICSs to mobilise NICE approvals

pharmaphorum

Join us on Wednesday 23rd November at 12:30 GMT / 13:30 CET / 7:30 am EST as the panel discuss how the Innovative Medicines Fund works, what the implications are for industry organisations in securing funding via this route, and how this will influence uptake of medicines recommended via a NICE technology appraisal. Angela McFarlane ?,

Medicine 110
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Key operational considerations to optimise decentralised clinical trials

pharmaphorum

IQVIA conducted a thorough analysis of 12 global DCT studies across three therapeutic areas and seven indications to compare DCTs’ value to key stakeholders with traditional trials. Tailoring the DCT technology strategy. Failures in patient engagement and retention can delay or stop a clinical trial.

article thumbnail

It’s time get real with healthcare’s commitment to net zero

pharmaphorum

IQVIA examined the top 100 companies by global sales revenue (IQVIA MIDAS) and extracted data on commitments and progress (Figure 1). About the author. He is involved in numerous projects related to ESG, as well as the interface between healthcare and digital technology.

article thumbnail

12 New Ways Companies Are Helping to Improve Adherence

PM360

Here are twelve of the best examples of programs, strategies, solutions, technology, and more that companies have developed or are using to keep patients on their prescribed therapies. That’s why it uses technological innovation to empower pharmacists to provide direct consultative care and boost medication adherence.

article thumbnail

From trial design for patients to trial design with patients: a key topic at DIA ’22

pharmaphorum

However, with COVID-19 re-emphasizing gaps in trial diversity and inclusion, there is a renewed focus on doing more, especially as we can leverage deep expertise and transformative technologies to knock down long-standing barriers. Various uses of interoperable technology that connect patients to clinical care and offers other DCT solutions.

article thumbnail

Automating – and optimising – HCP engagement to maximise commercial success

pharmaphorum

To ensure engagement accuracy and success, teams need a technology solution that can automate the updating of HCP segmentation data. To ensure an optimised engagement model critical to long-term success in today’s highly competitive commercial market, life sciences companies need to effectively leverage AI-powered technology.